Candriam SCA’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $139M | Buy |
395,351
+3,616
| +0.9% | +$1.29M | 0.72% | 26 |
|
|
2025
Q4 | $128M | Sell |
391,735
-53,485
| -12% | -$17M | 0.64% | 27 |
|
|
2025
Q3 | $126M | Sell |
445,220
-60,500
| -12% | -$17.5M | 0.66% | 27 |
|
|
2025
Q2 | $141M | Sell |
505,720
-483
| -0.1% | -$137K | 0.81% | 21 |
|
|
2025
Q1 | $158M | Sell |
506,203
-111,322
| -18% | -$32.9M | 0.99% | 19 |
|
|
2024
Q4 | $161M | Sell |
617,525
-195,571
| -24% | -$58M | 0.93% | 21 |
|
|
2024
Q3 | $262M | Buy |
813,096
+202,928
| +33% | +$66.4M | 1.51% | 10 |
|
|
2024
Q2 | $191M | Sell |
610,168
-78,192
| -11% | -$23M | 1.16% | 12 |
|
|
2024
Q1 | $196M | Sell |
688,360
-71,061
| -9% | -$20.8M | 1.25% | 11 |
|
|
2023
Q4 | $219M | Sell |
759,421
-102,316
| -12% | -$27.9M | 1.51% | 9 |
|
|
2023
Q3 | $232M | Buy |
861,737
+166,615
| +24% | +$41.6M | 1.64% | 10 |
|
|
2023
Q2 | $154M | Sell |
695,122
-310,684
| -31% | -$72.1M | 1.12% | 13 |
|
|
2023
Q1 | $224M | Buy |
1,005,806
+26,020
| +3% | +$6.39M | 1.55% | 8 |
|
|
2022
Q4 | $257M | Buy |
979,786
+13,861
| +1% | +$3.72M | 1.74% | 7 |
|
|
2022
Q3 | $218M | Buy |
965,925
+30,010
| +3% | +$7.27M | 1.53% | 8 |
|
|
2022
Q2 | $228M | Buy |
935,915
+2,182
| +0.2% | +$535K | 1.88% | 5 |
|
|
2022
Q1 | $226M | Sell |
933,733
-223,380
| -19% | -$51.3M | 1.54% | 8 |
|
|
2021
Q4 | $260M | Buy |
1,157,113
+47,309
| +4% | +$9.98M | 1.66% | 6 |
|
|
2021
Q3 | $236M | Buy |
1,109,804
+146,147
| +15% | +$33.6M | 1.6% | 6 |
|
|
2021
Q2 | $235M | Sell |
963,657
-360,548
| -27% | -$88.7M | 1.61% | 6 |
|
|
2021
Q1 | $292M | Buy |
1,324,205
+15
| +0% | +$3.58K | 2.43% | 4 |
|
|
2020
Q4 | $304M | Buy |
1,324,190
+61,831
| +5% | +$14.3M | 2.41% | 4 |
|
|
2020
Q3 | $321M | Buy |
1,262,359
+391,069
| +45% | +$96.9M | 3.01% | 2 |
|
|
2020
Q2 | $206M | Sell |
871,290
-33,678
| -4% | -$7.68M | 2.17% | 5 |
|
|
2020
Q1 | $213M | Buy |
904,968
+20
| +0% | +$4.37K | 2.36% | 2 |
|
|
2019
Q4 | $218M | Sell |
904,948
-3,432
| -0.4% | -$757K | 2.34% | 2 |
|
|
2019
Q3 | $176M | Sell |
908,380
-113,225
| -11% | -$21.7M | 2.33% | 2 |
|
|
2019
Q2 | $189M | Buy |
1,021,605
+6,646
| +0.7% | +$1.19M | 2.35% | 2 |
|
|
2019
Q1 | $194M | Buy |
1,014,959
+38,384
| +4% | +$7.33M | 2.48% | 2 |
|
|
2018
Q4 | $190M | Sell |
976,575
-98,475
| -9% | -$19.2M | 2.92% | 1 |
|
|
2018
Q3 | $223M | Buy |
1,075,050
+380,562
| +55% | +$75M | 2.96% | 1 |
|
|
2018
Q2 | $128M | Buy |
694,488
+51,039
| +8% | +$9.03M | 2.03% | 3 |
|
|
2018
Q1 | $110M | Buy |
643,449
+18,702
| +3% | +$3.43M | 1.87% | 3 |
|
|
2017
Q4 | $109M | Buy |
624,747
+161,172
| +35% | +$28.5M | 1.88% | 3 |
|
|
2017
Q3 | $86.4M | Sell |
463,575
-128,168
| -22% | -$22.7M | 1.51% | 6 |
|
|
2017
Q2 | $102M | Buy |
591,743
+63,181
| +12% | +$10.3M | 1.92% | 3 |
|
|
2017
Q1 | $86.7M | Sell |
528,562
-182,763
| -26% | -$30.4M | 1.68% | 5 |
|
|
2016
Q4 | $104M | Buy |
711,325
+74,647
| +12% | +$11.2M | 2.39% | 3 |
|
|
2016
Q3 | $106M | Buy |
636,678
+47,963
| +8% | +$8.11M | 2.55% | 1 |
|
|
2016
Q2 | $89.6M | Sell |
588,715
-111,618
| -16% | -$17.4M | 2.33% | 1 |
|
|
2016
Q1 | $104M | Buy |
+700,333
| New | +$104M | 2.61% | 3 |
|
|
2015
Q4 | – | Sell |
-776,974
| Closed | -$107M | – | 571 |
|
|
2015
Q3 | $107M | Sell |
776,974
-94,675
| -11% | -$14.9M | 2.64% | 2 |
|
|
2015
Q2 | $134M | Buy |
871,649
+76,688
| +10% | +$12.3M | 2.78% | 1 |
|
|
2015
Q1 | $127M | Buy |
794,961
+336,833
| +74% | +$53M | 2.56% | 1 |
|
|
2014
Q4 | $73M | Buy |
+458,128
| New | +$71.4M | 1.53% | 5 |
|
Other funds holding AMGN
VCM
VPM
Candriam SCA's AMGN Position: Q1 2026 in Review
Candriam SCA increased its Amgen (AMGN) stake by 0.92% in Q1 2026, buying an estimated $1.29M and bringing the position to 395,351 shares worth $139M. The position accounts for 0.72% of the portfolio, ranked #26.
Candriam SCA first reported a position in AMGN in Q4 2014 and has held it in 45 quarters since. The position peaked at $321M in Q3 2020. 3,129 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.
- Candriam SCA held 395,351 shares of Amgen worth $139M as of Q1 2026.
- Candriam SCA bought 3,616 Amgen shares in Q1 2026, an estimated $1.29M.
- Amgen made up 0.72% of Candriam SCA's portfolio in Q1 2026, its #26 holding.
- Candriam SCA first reported a position in Amgen in Q4 2014 and has held it in 45 quarters since.
- Candriam SCA's Amgen position peaked at $321M in Q3 2020.
- 3,129 funds tracked by Wall St. Rank held Amgen as of Q1 2026.
Based on Candriam SCA's 13F filing for Q1 2026, filed 30 Apr 2026.